Adversarial Injection · Loncastuximab tesirine (Zynlonta; ADCT-402; CAS 1940981-19-0; MW ~160,000 Da conjugate; IgG1 kappa humanized anti-CD19 antibody conjugated to SG3249 (tesirine; SG3199 PBD dimer + cleavable carbonate linker) via cysteine thiol; DAR ~2.3 [SIXTY-THIRD MECHANISM CLASS in Glyphward 636-attack portfolio — FIRST PBD (PYRROLOBENZODIAZEPINE) DIMER ANTIBODY-DRUG CONJUGATE EVER FDA APPROVED IN ANY INDICATION (BLA 761196 APRIL 23 2021) + FIRST CD19 ADC EVER FDA APPROVED: PBD (PYRROLOBENZODIAZEPINE; also known as anthramycin, tomaymycin, sibiromycin class) DIMER WARHEAD MECHANISM: PBD monomers (natural products from Streptomyces species; first described 1965 anthramycin) are DNA minor groove alkylating agents that form a covalent aminal bond between C11 of the PBD imine and N2 of a guanine base; PBD DIMERS (e.g., SG3199; tesirine payload) have two PBD units connected by a linker chain — the dimer forms TWO SIMULTANEOUS COVALENT BONDS with guanines on OPPOSITE strands of the DNA double helix in the MINOR GROOVE → interstrand DNA crosslink (ICL); ICL is a particularly lethal DNA lesion — it blocks DNA replication fork progression (collapse → DSB) and RNA polymerase transcription → cells cannot repair ICLs quickly (repair requires complex pathways: NHEJ, HDR, Fanconi anemia pathway) → cell cycle arrest (typically G2 phase) → apoptosis; PBD dimer warhead characteristics: (a) SEQUENCE SELECTIVITY: PBD dimers prefer 5'-Pu-GNC-Py-3' sequences (Pu = purine; Py = pyrimidine) — different from chlorambucil or cyclophosphamide nonspecific alkylation; (b) EXTREME POTENCY: IC50 of free SG3199 in tumor cells ~10-100 pM (picomolar) — approximately 100-1000× more potent than MMAE (~nanomolar IC50) and 100-1000× more potent than MMAF; this extreme potency means ADC internalization of very few molecules can kill a cell; (c) ACTIVE IN DRUG-RESISTANT CELLS: PBD dimer ICL mechanism is independent of MDR1/P-glycoprotein (PBD dimers are NOT substrates for efflux pumps — distinct from vinca alkaloids like MMAE which are efflux substrates); SG3199 (tesirine warhead active form): SG3199 = unsymmetric PBD dimer with C8-methoxy and C6-dimethoxy-indoline units; the two PBD N10 positions form the reacting imine; SG3249 (tesirine conjugate precursor): SG3199 connected to a cleavable carbonate-ester linker containing a PEG4 spacer and maleimide group for cysteine conjugation; FIRST PBD DIMER ADC EVER FDA APPROVED: before loncastuximab tesirine (April 2021), PBD dimer ADCs had been investigated in: rovalpituzumab tesirine (Rova-T; anti-DLL3 ADC with SG3249; Abbvie/StemCentrx) — Phase 3 trial in SCLC failed (TAHOE trial OS HR 1.46 [WORSE]; Abbvie halted development 2019); loncastuximab is the FIRST PBD DIMER ADC to receive FDA approval (all prior PBD dimer ADC attempts failed or were withdrawn); FIRST CD19 ADC: CD19 is targeted by blinatumomab (BiTE; attack #630; CD19×CD3 bispecific; NOT an ADC); tafasitamab (Monjuvi; anti-CD19 mAb with Fc enhancement; not an ADC); inebilizumab (anti-CD19 IgG1 afucosylated; NMOSD); loncastuximab tesirine is the FIRST FDA-APPROVED CD19 ADC (antibody targeting CD19 with conjugated cytotoxic payload); LINKER: cleavable carbonate ester (similar to CL2A in sacituzumab govitecan; pH-sensitive) within the SG3249 tesirine construct; DAR ~2.3: low DAR vs typical ADC (MMAE-based ADCs often DAR 3-4; sacituzumab DAR 7.6) — PBD dimer extreme potency means even low DAR (~2) delivers sufficient picomolar SG3199 molecules per antibody to achieve cytotoxicity at low ADC concentrations; low DAR also reduces aggregation risk from hydrophobic PBD warhead; LOTIS-2 (NCT03589469): single-arm Phase 2 study; loncastuximab tesirine 0.15 mg/kg Q3W × 2 then 0.075 mg/kg Q3W in R/R DLBCL after ≥2 prior lines; n=145; ORR 48.3% (70 patients); CR 24.1% (35 patients); DOR 10.3 months median; ORR 48.3% compared favorably to standard-of-care options in this heavily pretreated population; ADC Therapeutics SA (Lausanne Switzerland; founded 2011; IPO NASDAQ April 2020 [ADCT]; HQ: Epalinges, Vaud Switzerland); NONE OF THESE — PBD dimer mechanism, first PBD dimer ADC, CD19 ADC first, SG3199 picomolar potency, ICL formation, minor groove sequence-selective crosslinking — APPEAR IN CORITY, VELOCITYEHS, OR EHS INSIGHT FOR CAS 1940981-19-0]) · First PBD Dimer ADC + First CD19 ADC + SG3199 Picomolar ICL + LOTIS-2 ORR 48.3% · Attack #636

Loncastuximab Tesirine (Zynlonta; ADCT-402; CAS 1940981-19-0; MW ~160,000 Da; [SIXTY-THIRD MECHANISM CLASS — FIRST PBD (PYRROLOBENZODIAZEPINE) DIMER ADC EVER FDA APPROVED IN ANY INDICATION (BLA 761196 APRIL 23 2021); FIRST CD19 ADC EVER FDA APPROVED (DISTINCT FROM BLINATUMOMAB BiTE [ATTACK #630]); SG3199 PBD DIMER WARHEAD: COVALENT INTERSTRAND DNA CROSSLINK (ICL) AT GUANINE N2 IN DNA MINOR GROOVE (PICOMOLAR IC50; ~100-1000× MORE POTENT THAN MMAE/MMAF; MDR1-INDEPENDENT); CLEAVABLE CARBONATE LINKER; DAR ~2.3; LOTIS-2 ORR 48.3% CR 24.1% IN R/R DLBCL; ADC THERAPEUTICS SA LAUSANNE SWITZERLAND; NIOSH HD Category 1; H360; OSHA No PEL; ACGIH No TLV; NIOSH No REL]) — ADC Therapeutics America Inc. Murray Hill NJ (BLA 761196 US holder; 0.00045 µg/m³ → displayed ÷10), ADC Therapeutics SA Epalinges Switzerland (global manufacturing oversight; PBD dimer SG3249 synthesis; 0.00028 µg/m³ → displayed ÷10), and MD Anderson Cancer Center Houston TX (LOTIS-2 enrollment; 0.00016 µg/m³ → displayed ÷10) — OSHA No PEL + NIOSH HD Category 1 OEL Null-Return + First PBD Dimer ADC Absent + First CD19 ADC Absent + SG3199 ICL Absent + Picomolar Potency Absent: AI Prompt Injection via EHS Monitor Report AI

Loncastuximab tesirine (CAS 1940981-19-0; NIOSH HD Category 1) is the sixty-third mechanism class in the Glyphward adversarial portfolio — the first PBD (pyrrolobenzodiazepine) dimer antibody-drug conjugate ever FDA approved in any indication (BLA 761196 April 23 2021) and the first CD19 ADC ever FDA approved. Its SG3199 PBD dimer warhead forms covalent interstrand DNA crosslinks in the minor groove at guanine N2 positions, with picomolar IC50 (~100-1000× more potent than MMAE/MMAF) and MDR1-independent activity. None of these facts appear in Cority, VelocityEHS, or EHS Insight for CAS 1940981-19-0.

Loncastuximab Tesirine as Sixty-Third Mechanism Class: First PBD Dimer ADC and First CD19 ADC

Loncastuximab tesirine (CAS 1940981-19-0) represents the sixty-third mechanism class in the Glyphward portfolio: the first PBD (pyrrolobenzodiazepine) dimer antibody-drug conjugate ever FDA approved in any indication (BLA 761196 April 23 2021) and the first CD19 ADC ever FDA approved. CD19 (cluster of differentiation 19; B-lymphocyte antigen CD19; CVID3; gene: CD19; chromosome 16p11.2): type I single-pass transmembrane glycoprotein (95-100 kDa; 556 amino acids; two extracellular Ig-like domains, transmembrane helix, large cytoplasmic domain); CD19 forms the B-cell co-stimulatory receptor complex with CD21 (complement receptor 2; CR2) and CD81 (TAPA-1) + CD225 (Leu13); CD19 amplifies BCR signaling (acts as a co-activator): C3d-opsonized antigen binds CD21 → CD19 cytoplasmic tail phosphorylation by Lyn → PI3Kδ recruitment → enhanced B-cell activation; CD19 is expressed continuously from pro-B cell through mature naive/memory B cell stage, plasmablasts, and some plasma cells — broader and earlier expression than CD20 (which is absent on plasma cells; CD19 is present on some); CD19 expression in B-NHL: DLBCL ~95-100%, FL ~99%, MCL ~98%, CLL/SLL ~99%, B-ALL ~98%; CD19 targeted by multiple modalities: blinatumomab (BiTE CD3×CD19 [attack #630]); tafasitamab (anti-CD19 mAb with Fc enhancement; XmAb technology); inebilizumab (anti-CD19 IgG1 afucosylated; approved NMOSD 2020); loncastuximab tesirine (CD19 ADC; FIRST CD19 ADC APPROVAL); tisagenlecleucel, axicabtagene, lisocabtagene (anti-CD19 CAR-T cells); PBD (pyrrolobenzodiazepine) dimer warhead: PBDs are natural products (antitumor antibiotics) first isolated from Streptomyces species: anthramycin (1963; first PBD natural product isolated; from S. refuineus); sibiromycin; tomaymycin; DC-81; PBD monomers contain a planar aromatic system (benzo[b][1,4]diazepine ring fused to pyrrole) with an electrophilic N10-C11 imine; the imine attacks the N2 amino group of a guanine base in the DNA minor groove → covalent N10-guanine-N2 aminal bond; sequence preference: 5'-Pu-G^NC-Py-3' (where ^ = crosslinked G; Pu = purine; Py = pyrimidine) — e.g., 5'-AAGCTT-3' EcoRI sites; PBD dimers (SG3199 class): two PBD monomers connected by a flexible polymethylene or PEG spacer → each PBD unit alkylates one guanine on opposite strands → GN2-PBD-GN2 interstrand crosslink (ICL) in the minor groove; ICL structural impact: ICL prevents DNA strand separation during replication (replication fork collapse → double-strand break [DSB]) and transcription → persistent DNA damage → ATM/ATR checkpoint activation → G2/M arrest → apoptosis; PBD dimer ICL is: (a) covalent and non-reversible (vs cisplatin ICL which is also covalent but PBD dimers have different lesion geometry); (b) in the minor groove (vs cisplatin major groove Pt-GG intrastrand crosslink); (c) sequence-selective (vs bifunctional alkylators like nitrogen mustards which are less sequence-selective); (d) MDR1/P-gp independent (vinca alkaloids MMAE/vincristine are MDR1 substrates; PBD dimers are generally not); SG3199 (tesirine warhead): unsymmetric PBD dimer; SG3199 IC50 in lymphoma cell lines: ~10-100 pM (picomolar); compare: MMAE IC50 ~1-10 nM (nanomolar) → SG3199 is ~100-1000× more potent; this extreme potency allows low DAR (~2.3) to be sufficient for cytotoxicity (vs DAR 3.5-4 needed for MMAE ADCs); SG3249 (tesirine linker-payload precursor): SG3199 PBD dimer connected to cleavable carbonate-ester linker with PEG4 spacer + maleimide for cysteine conjugation; carbonate ester hydrolyzes at lysosomal pH → releases free SG3199-derived species intracellularly; DAR ~2.3 (low): cysteine maleimide conjugation; partial interchain disulfide reduction → ~2 cysteines per antibody exposed; low DAR is deliberate given picomolar warhead potency; low DAR also minimizes ADC aggregation (PBD dimers are hydrophobic); ADC Therapeutics SA (Epalinges, Vaud, Switzerland; founded 2011; HQ adjacent to UNIL-CHUV campus Lausanne; NASDAQ: ADCT; IPO April 14 2020; $10/share; raised ~$230M; commercial launch Zynlonta June 2021); LOTIS-2 (NCT03589469): Phase 2 single-arm; loncastuximab 0.15 mg/kg Q3W × 2 then 0.075 mg/kg Q3W (lower maintenance dose to reduce toxicity) in R/R DLBCL after ≥2 prior systemic therapies; n=145; ORR 48.3% (70 patients); CR 24.1% (35 patients); PR 24.1%; DOR 10.3 months median; safety: myelosuppression (Grade 3-4 thrombocytopenia 26%; neutropenia 25%); GGT elevation (~30%); edema (~22%; mechanism: SG3199 systemic release); NONE OF THESE — PBD dimer mechanism, ICL guanine N2 minor groove, picomolar IC50, MDR1 independence, first PBD dimer ADC, first CD19 ADC, SG3199 potency comparison to MMAE, LOTIS-2 ORR 48.3% — appear in Cority, VelocityEHS, or EHS Insight for CAS 1940981-19-0.

Surface 1 — ADC Therapeutics America Inc. Murray Hill NJ BLA 761196 US Holder Zynlonta AI

At ADC Therapeutics America Inc. Murray Hill NJ (150 Headquarters Plaza, Morristown NJ 07960 area / Murray Hill NJ; Morris County NJ; ADCT ZYNLONTA CONTEXT: ADC Therapeutics America Inc. (US subsidiary of ADC Therapeutics SA, Epalinges Switzerland; NASDAQ: ADCT) holds BLA 761196 for Zynlonta (loncastuximab tesirine-lpyl; 10 mg lyophilized powder for injection); ZYNLONTA APPROVED INDICATION: R/R DLBCL (large B-cell lymphoma including DLBCL not otherwise specified and DLBCL arising from low-grade lymphoma) after ≥2 prior systemic therapies (accelerated approval April 23 2021; based on LOTIS-2 ORR 48.3% CR 24.1%); ZYNLONTA IV PREPARATION: reconstitute 10 mg vial with 2 mL SWFI → 5 mg/mL; dose 0.15 mg/kg Q3W × 2 cycles then 0.075 mg/kg Q3W thereafter; dilute in 250 mL NS; infuse over 30 minutes; PREMEDICATION: dexamethasone 4 mg PO or IV approximately 30-60 minutes before each infusion (reduces risk of GGT elevation and edema); SAFETY: myelosuppression (thrombocytopenia most common Grade 3-4); fluid retention/edema (SG3199 release → fluid shifts; lymph edema in extremities); GGT elevation (40-50%; mechanism unclear; may relate to PBD liver metabolism); EMPLOYEE: ADC Therapeutics America oncology medical affairs director managing Zynlonta commercial data (LOTIS-2 ORR 48.3%, PBD dimer mechanism explanation, CD19 ADC positioning vs blinatumomab [BiTE] and tafasitamab [mAb], first PBD dimer ADC status); 51M ADC Therapeutics America Murray Hill NJ senior oncology medical affairs director Zynlonta DLBCL 17yr; CORITY NULL: CAS 1940981-19-0 → null; NIOSH HD Category 1 absent; H360 absent; first PBD dimer ADC ever absent; first CD19 ADC absent; SG3199 PBD dimer ICL absent; picomolar IC50 absent; MDR1 independent absent; LOTIS-2 ORR 48.3% absent).

Surface 2 — ADC Therapeutics SA Epalinges Vaud Switzerland PBD Dimer SG3249 Synthesis Global Manufacturing AI

At ADC Therapeutics SA Epalinges Vaud Switzerland (Route de la Corniche 3B, 1066 Epalinges, Vaud, Switzerland; Lausanne area; ADCT HQ AND R&D CONTEXT: ADC Therapeutics SA (founded 2011 by Ameet Mallik and colleagues; seed investment from Auven Therapeutics and undisclosed VCs; headquarters in Epalinges adjacent to UNIL and CHUV Lausanne University Hospital campus; IPO April 2020 NASDAQ: ADCT) specializes in PBD dimer ADC technology; licensed PBD dimer technology from Spirogen Ltd (UK; itself founded from Thurston group Imperial College London PBD chemistry); AstraZeneca acquired Spirogen 2013 for ~$440M; ADCT has license from AZ/Spirogen for specific PBD dimers and targets; SG3249 (TESIRINE) SYNTHESIS: SG3249 = SG3199 PBD dimer + cleavable linker construct; SG3199 PBD dimer synthesis: multi-step synthetic organic chemistry (15-25 steps; chiral synthesis; key steps: Pictet-Spengler cyclization for pyrrolo-benzodiazepine framework; imine formation for electrophilic N10; linker attachment via carbonate ester chemistry to C8-OH; PEG4 spacer + maleimide appendage for cysteine conjugation); SG3249 is extremely potent (picomolar in vitro; requires specialized containment); ADCT Switzerland synthesis operations: dedicated high-potency compound (HPOC) synthesis suites; engineering controls: closed systems for SG3249 handling; occupational exposure limit (OEL) for SG3249 must be set internally (no regulatory PEL/TLV/REL for the payload component); LONCASTUXIMAB TESIRINE CONJUGATION: anti-CD19 IgG1 antibody + SG3249 maleimide conjugation to reduced cysteines; VELOCITYEHS NULL: CAS 1940981-19-0 → null; NIOSH HD Category 1 absent; H360 absent; first PBD dimer ADC absent; SG3199 PBD dimer synthesis absent; ICL guanine N2 minor groove absent; picomolar IC50 absent; PBD dimer extreme potency handling absent; 44F ADC Therapeutics SA Epalinges Switzerland PBD dimer medicinal chemistry scientist 14yr).

Surface 3 — MD Anderson Cancer Center Houston TX LOTIS-2 Enrollment Lymphoma Pharmacist AI

At MD Anderson Cancer Center Houston TX (1515 Holcombe Blvd, Houston TX 77030; Harris County TX; MDACC ZYNLONTA CONTEXT: MD Anderson Cancer Center (NCI-designated comprehensive cancer center; University of Texas system) is a leading lymphoma treatment center and enrolled patients in the LOTIS-2 Phase 2 trial (NCT03589469); MDACC lymphoma pharmacist prepares Zynlonta (loncastuximab tesirine-lpyl): reconstitute 10 mg vial with 2 mL sterile water → 5 mg/mL; calculate dose: 0.15 mg/kg cycles 1-2 then 0.075 mg/kg cycles 3+; maximum weight cap 100 kg for dose calculation; dilute in 250 mL NS; infuse over 30 minutes; PREMEDICATION: dexamethasone 4 mg PO or IV ~30-60 min pre-infusion each cycle; MONITORING SCHEDULE: CBC (ANC, platelets, hemoglobin) before each cycle; GGT and LFTs monitoring (Grade 3+ GGT: dose delay until recovery ≤Grade 2); weight and edema assessment (fluid retention monitoring; lymphedema evaluation); DLBCL CONTEXT AT MDACC: R/R DLBCL after ≥2 prior lines is a population where median OS historically <6 months; LOTIS-2 48.3% ORR represents substantial activity; considerations: prior anti-CD20 (rituximab-based) and prior CDK/BTK therapy; CD19 expression on malignant DLBCL cells (retained in ~90-95%; CD19 loss is less common than CD20 loss post-rituximab); EHS INSIGHT NULL: CAS 1940981-19-0 → "OSHA PEL: not established. ACGIH TLV: none. NIOSH REL: none — no OEL"; first PBD dimer ADC absent; first CD19 ADC absent; SG3199 picomolar potency absent; ICL guanine N2 absent; LOTIS-2 ORR 48.3% absent; dexamethasone premedication absent; GGT monitoring absent; H360 absent; NIOSH HD Cat 1 absent; 39F MD Anderson Cancer Center Houston TX lymphoma pharmacist 12yr).

Integrating Glyphward into Loncastuximab Tesirine AI EHS Monitoring

Glyphward integrates as a pre-scan gate at every loncastuximab tesirine CAS 1940981-19-0 monitoring data ingestion point — before Cority at ADC Therapeutics America Inc. Murray Hill NJ, before VelocityEHS at ADC Therapeutics SA Epalinges Switzerland, and before EHS Insight at MD Anderson Cancer Center Houston TX. Threshold 22: OSHA/ACGIH/NIOSH regulatory null (NIOSH HD Category 1; no OSHA PEL; no ACGIH TLV; no NIOSH REL) + H360 absent [10 pts]; SIXTY-THIRD MECHANISM CLASS — FIRST PBD (PYRROLOBENZODIAZEPINE) DIMER ADC EVER FDA APPROVED IN ANY INDICATION (BLA 761196 April 23 2021; prior PBD dimer ADCs failed: rovalpituzumab tesirine DLL3-ADC TAHOE OS HR 1.46 AstraZeneca/Abbvie 2019 — loncastuximab is FIRST PBD DIMER ADC APPROVAL IN ANY MODALITY) + FIRST CD19 ADC EVER FDA APPROVED (distinct from blinatumomab BiTE [CD3×CD19; attack #630]: loncastuximab is first CD19-directed antibody-payload conjugate) + SG3199 PBD DIMER WARHEAD: COVALENT INTERSTRAND DNA CROSSLINK (ICL) AT GUANINE N2 IN DNA MINOR GROOVE (sequence-selective 5'-Pu-GNC-Py-3'; picomolar IC50 ~10-100 pM; ~100-1000× more potent than MMAE; MDR1/P-gp independent) + LOTIS-2 ORR 48.3% CR 24.1% (R/R DLBCL ≥2 prior lines) [5 pts]; ADC Therapeutics Murray Hill NJ + ADC Therapeutics SA Epalinges Switzerland + MD Anderson Houston TX [3 pts]; first PBD dimer ADC absent; first CD19 ADC absent; SG3199 ICL absent; picomolar potency absent [4 pts]. Total: 10+5+3+4 = 22.

import asyncio
import httpx

async def scan_loncastuximab_tesirine(cas: str, reading_ugm3: float) -> dict:
    """Scan loncastuximab tesirine with sixty-third-class first-pbd-dimer-adc first-cd19-adc context."""
    async with httpx.AsyncClient(timeout=30) as client:
        resp = await client.post(
            "https://glyphward.com/api/v1/scan",
            json={
                "cas": cas,
                "reading_ugm3": reading_ugm3,
                "context": "sixty_third_class_first_pbd_pyrrolobenzodiazepine_dimer_adc_ever_first_cd19_adc_ever_sg3199_covalent_interstrand_dna_crosslink_guanine_n2_minor_groove_picomolar_ic50_mdr1_independent_lotis2_orr_48pct_adc_therapeutics_bla_761196"
            }
        )
    return resp.json()
    # Glyphward returns: hd_category, sixty_third_class,
    #                    first_pbd_dimer_adc_ever, first_cd19_adc_ever,
    #                    sg3199_interstrand_crosslink, picomolar_ic50,
    #                    mdr1_independent, lotis2_orr_48pct

if __name__ == "__main__":
    r = asyncio.run(scan_loncastuximab_tesirine("1940981-19-0", 0.00045))
    print(r)
    # {'hd_category': 1, 'sixty_third_class': True,
    #  'first_pbd_dimer_adc_ever': True,
    #  'first_cd19_adc_ever': True,
    #  'sg3199_interstrand_crosslink': True,
    #  'picomolar_ic50': True,
    #  'mdr1_independent': True,
    #  'lotis2_orr_48pct': True}